<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255966</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-H-O-1821</org_study_id>
    <nct_id>NCT04255966</nct_id>
  </id_info>
  <brief_title>Plasmafit® Revision Structan® Hip Endoprosthesis Cup</brief_title>
  <official_title>Prospective, Multi-centric, Comparative, Long-term Clinical Follow-Up Study for the Evidence of Safety and Performance Indicators of the Plasmafit® Revision Structan® Hip Endoprosthesis Cup</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to collect clinical and radiological results of the
      new Plasmafit® Revision Structan® Hip Endoprosthesis Cup in a standard patient population and
      when used in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Harris Hip Score (Functional results of the operated hip) over time</measure>
    <time_frame>up to five years postoperatively</time_frame>
    <description>The functional results of the operated hip will be assessed with the Harris Hip Score (HHS) and evaluated over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of the implant</measure>
    <time_frame>up to five years postoperatively</time_frame>
    <description>Any removal or exchange of the acetabular cup or the polyethylene inlay is defined as revision.
A removal of the stem is not evaluated as acetabular revision but will be documented and evaluated as part of postoperative complications.
The revision-free survival will be assessed using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life over time</measure>
    <time_frame>up to five years postoperatively</time_frame>
    <description>EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Assessment: Osseointegration of the cup over time</measure>
    <time_frame>at 3 months, 24 months, 5 years follow-up</time_frame>
    <description>The acetabular component in AP view is divided into the three regions I-III as defined by DeLee-Charnley. All three regions will be assessed for osteolysis the implant, to allow an estimation of the osseous integration and stability of the implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological assessment: Radiographic loosening of the cup over time</measure>
    <time_frame>at 3 months, 24 months, 5 years follow-up</time_frame>
    <description>The acetabular component in AP view is divided into the three regions I-III as defined by DeLee-Charnley. All three regions will be assessed for and radiolucent lines around the implant, to allow an estimation of the osseous integration and stability of the implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical problems during surgery</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Technical problems with instruments, implants or containers, instrument related issues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impingement</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The incidence of impingement during intraoperative mobilization is documented;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General handling of instruments / containers</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Complaints or problems with the handling of instruments, implants or containers, instrument related issues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>up to 5 years postoperatively</time_frame>
    <description>All complications in the postoperative course are recorded</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteolysis</condition>
  <condition>Arthroplasty Complications</condition>
  <condition>Instability of Prosthetic Joint</condition>
  <condition>Degenerative Osteoarthritis</condition>
  <condition>Rheumatic Arthritis</condition>
  <condition>Fractures, Hip</condition>
  <condition>Femoral Head Avascular Necrosis</condition>
  <condition>Prosthesis Failure</condition>
  <arm_group>
    <arm_group_label>Plasmafit® Revision Structan®</arm_group_label>
    <description>Plasmafit® Revision Structan® Hip Endoprosthesis Cup</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasmafit® Revision Structan®</intervention_name>
    <description>Plasmafit® Revision Structan® Hip Endoprosthesis Cup</description>
    <arm_group_label>Plasmafit® Revision Structan®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having acute disorders of the hip, requiring primary or revision surgery, which
        cannot be treated by other therapies:

          -  Degenerative osteoarthritis

          -  Rheumatic arthritis

          -  Fractures of the joint

          -  Femoral head necrosis

          -  Revision surgery where a sufficient intraoperative press-fit can be achieved
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Indication for the cementless Plasmafit® Revision Structan® Hip Endoprosthesis Cup
             (primary and revision cases, with bone conditions typically demanding a press-fit
             revision cup)

          -  Written informed consent

          -  Cases where a press-fit cup fixation is possible

        Exclusion Criteria

          -  Patients &lt; 18 years

          -  Pregnant patients

          -  Patients not able to comply with the study demands, i.e. follow-up visits (mentally or
             physically)

          -  Patient has an infection in the hip joint region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Landgraeber, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerstin Bergmann</last_name>
    <phone>+49-7461-95</phone>
    <email>kerstin.bergmann@aesculap.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas Reina, Prof. Dr.</last_name>
      <phone>+33-</phone>
      <email>reina.n@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orthopädische Klinik König-Ludwig-Haus</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rudert, Prof. Dr.</last_name>
      <phone>+49 931 803-0</phone>
      <email>m-rudert.klh@uni-wuerzburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzogin Elisabeth Hospital</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachse</state>
        <zip>38124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Karl-Dieter Heller, Prof. Dr.</last_name>
      <phone>+49 531 699-0</phone>
      <email>KD.Heller@heh-bs.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Holger Haas, Dr.</last_name>
      <phone>+49 228 506-0</phone>
      <email>h.haas@gk-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Landgraeber, Prof. Dr.</last_name>
      <phone>+49 6841-16</phone>
      <email>Stefan.Landgraeber@uks.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Revision of the acetabular implant</keyword>
  <keyword>orthopaedic surgery</keyword>
  <keyword>osteolysis</keyword>
  <keyword>wear particles</keyword>
  <keyword>cup loosening</keyword>
  <keyword>malpositioned cup</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteolysis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Prosthesis Failure</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

